Literature DB >> 22682893

Hexavalent chromium reduction kinetics in rodent stomach contents.

Deborah M Proctor1, Mina Suh, Lesa L Aylward, Christopher R Kirman, Mark A Harris, Chad M Thompson, Hakan Gürleyük, Russell Gerads, Laurie C Haws, Sean M Hays.   

Abstract

Reduction of hexavalent chromium (Cr(VI)) to trivalent chromium (Cr(III)) in the stomach prior to absorption is a well-recognized detoxification process thought to limit the toxicity of ingested Cr(VI). However, administration of high concentrations of Cr(VI) in drinking water cause mouse small intestinal tumors, and quantitative measures of Cr(VI) reduction rate and capacity for rodent stomach contents are needed for interspecies extrapolation using physiologically-based toxicokinetic (PBTK) models. Ex vivo studies using stomach contents of rats and mice were conducted to quantify Cr(VI) reduction rate and capacity for loading rates (1-400 mg Cr(VI)L(-1) stomach contents) in the range of recent bioassays. Cr(VI) reduction was measured with speciated isotope dilution mass spectrometry to quantify dynamic Cr(VI) and Cr(III) concentrations in stomach contents at select time points over 1 h. Cr(VI) reduction followed mixed second-order kinetics, dependent upon concentrations of both Cr(VI) and the native reducing agents. Approximately 16 mg Cr(VI)-equivalents of reducing capacity per L of fed stomach contents (containing gastric secretions, saliva, water and food) was found for both species. The second-order rate constants were 0.2 and 0.3 L mg(-1) h(-1) for mice and rats, respectively. These findings support that, at the doses that caused cancer in the mouse small intestine (≥ 20 mg Cr(VI)L(-1) in drinking water), the reducing capacity of stomach contents was likely exceeded. Thus, for extrapolation of target tissue dose in risk assessment, PBTK models are necessary to account for competing kinetic rates including second order capacity-limited reduction of Cr(VI) to Cr(III).
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682893     DOI: 10.1016/j.chemosphere.2012.04.065

Source DB:  PubMed          Journal:  Chemosphere        ISSN: 0045-6535            Impact factor:   7.086


  7 in total

1.  Different roles of ROS and Nrf2 in Cr(VI)-induced inflammatory responses in normal and Cr(VI)-transformed cells.

Authors:  Ram Vinod Roy; Poyil Pratheeshkumar; Yong-Ok Son; Lei Wang; John Andrew Hitron; Sasidharan Padmaja Divya; Zhuo Zhang; Xianglin Shi
Journal:  Toxicol Appl Pharmacol       Date:  2016-07-26       Impact factor: 4.219

Review 2.  Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans.

Authors:  Chad M Thompson; Deborah M Proctor; Mina Suh; Laurie C Haws; Christopher R Kirman; Mark A Harris
Journal:  Crit Rev Toxicol       Date:  2013-03       Impact factor: 5.635

3.  Synchrotron-based imaging of chromium and γ-H2AX immunostaining in the duodenum following repeated exposure to Cr(VI) in drinking water.

Authors:  Chad M Thompson; Jennifer Seiter; Mark A Chappell; Ryan V Tappero; Deborah M Proctor; Mina Suh; Jeffrey C Wolf; Laurie C Haws; Rock Vitale; Liz Mittal; Christopher R Kirman; Sean M Hays; Mark A Harris
Journal:  Toxicol Sci       Date:  2014-10-28       Impact factor: 4.849

4.  Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment.

Authors:  Chad M Thompson; Julia E Rager; Mina Suh; Caroline L Ring; Deborah M Proctor; Laurie C Haws; Rebecca C Fry; Mark A Harris
Journal:  Environ Mol Mutagen       Date:  2016-11-15       Impact factor: 3.216

5.  Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis.

Authors:  Chad M Thompson; Yuriy Fedorov; Daniel D Brown; Mina Suh; Deborah M Proctor; Liz Kuriakose; Laurie C Haws; Mark A Harris
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

6.  A chronic oral reference dose for hexavalent chromium-induced intestinal cancer.

Authors:  Chad M Thompson; Christopher R Kirman; Deborah M Proctor; Laurie C Haws; Mina Suh; Sean M Hays; J Gregory Hixon; Mark A Harris
Journal:  J Appl Toxicol       Date:  2013-08-14       Impact factor: 3.446

7.  Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium.

Authors:  Chad M Thompson; Christopher R Kirman; Sean M Hays; Mina Suh; Seneca E Harvey; Deborah M Proctor; Julia E Rager; Laurie C Haws; Mark A Harris
Journal:  J Appl Toxicol       Date:  2017-10-24       Impact factor: 3.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.